130927-83-2

Basic information

• Product Name: 1-Benzyl-4-piperidine aceticacid
• Synonyms: 1-Benzyl-4-piperidine aceticacid;(1-benzylpiperidin-4-yl)acetic acid(SALTDATA: HCl)
• CAS NO: 130927-83-2
• Molecular Formula: C₁₄H₁₉NO₂
• Molecular Weight: 233.30616
• Product Categories: pharmacetical
• Mol File: 130927-83-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 378°Cat760mmHg
• Flash Point: 182.4°C
• Appearance: /
• Density: 1.121g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 4.49±0.10(Predicted)
• CAS DataBase Reference: 1-Benzyl-4-piperidine aceticacid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-piperidine aceticacid(130927-83-2)
• EPA Substance Registry System: 1-Benzyl-4-piperidine aceticacid(130927-83-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 130927-83-2(Hazardous Substances Data)

Usage

General Description

1-Benzyl-4-piperidine acetic acid is a chemical compound with the molecular formula C17H21NO2. It is a white crystalline powder that is soluble in organic solvents and has a melting point of 148-152°C. 1-Benzyl-4-piperidine aceticacid is a derivative of piperidine and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals due to its potential biological activity. It also has applications in the field of neuroscience research, particularly in the study of the central nervous system and the development of new drugs for the treatment of various neurological disorders. Additionally, it has been investigated for its potential as an analgesic and anti-inflammatory agent, as well as for its use in the production of certain types of polymers.

InChI:InChI=1/C14H19NO2/c16-14(17)10-12-6-8-15(9-7-12)11-13-4-2-1-3-5-13/h1-5,12H,6-11H2,(H,16,17)

Upstream product

• 120014-06-4 donepezil 
• 100-39-0 benzyl bromide 
• 100-52-7 benzaldehyde 
• 54401-85-3 pyridin-4-yl-acetic acid ethyl ester 
• 59184-90-6 ethyl (piperidin-4-yl)acetate 
• 78056-67-4 1-(phenylmethyl)-4-piperidineacetonitrile 
• 71879-59-9 ethyl (1-benzylpiperidin-4-yl)acetate 

Downstream Products

• 211631-82-2 2-(1-Benzyl-piperidin-4-yl)-N-[bis-(4-fluoro-phenyl)-methyl]-acetamide 
• 333364-03-7 4-[2-((diphenylmethyl)amino)ethyl]-1-(phenylmethyl)piperidine 
• 364385-38-6 2-[(1-benzyl-4-piperidinyl)methyl]-6-bromooxazolo[4,5-b]pyridine 

Relevant articles and documents

Synthesis and in vivo evaluation of 3-[11C]methyl-(3-methoxy-naphthalen)-2-yl-(1-benzyl-piperidin)-4-yl-acetate (SB-235753), as a putative dopamine D4 receptors antagonist for PET

(3-Methoxy-naphthalen)-2-yl-(1-benzyl-piperidin)-4-yl-acetate (SB-235753) was labelled with 11C (t(1/2) = 20.4 min) as a putative radioligand for the non-invasive assessment of Dopamine D4 receptors in vivo with positron emission tomography (PET). The precursor for the radiosynthesis 3-hydroxynaphthyl-2-[(N-benzyl)-piperidyl]-acetate hydrochloride was prepared by a four-step synthesis starting from ethyl-4-pyridyl acetate. The radiolabelling consisted of methylation with [11C]methyltriflate in dimethylformamide in the presence of potassium hydroxide. [11C]SB-235753, was synthesised in 30 min with a radiochemical yield of 10 ± 5% (EOS, non-decay corrected) with 99% radiochemical purity and specific radioactivity of 10 ± 3 Ci/μmol. Biodistribution studies in rats with [11C]SB-235753 showed the uniform distribution of the tracer within different areas of the murine brain. At 30 min after injection 99% of the radioligand in plasma and 100% in cerebellum was metabolised. These findings suggest that [11C]SB-235753 can not be a suitable tracer for dopamine D4 receptor studies with PET.

Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin

A novel series of compounds obtained by fusing the acetylcholinesterase (AChE) inhibitor donepezil and the antioxidant melatonin were designed as multi-target-directed ligands for the treatment of Alzheimer's disease (AD). In vitro assay indicated that most of the target compounds exhibited a significant ability to inhibit acetylcholinesterase (eeAChE and hAChE), butyrylcholinesterase (eqBuChE and hBuChE), and β-amyloid (Aβ) aggregation, and to act as potential antioxidants and biometal chelators. Especially, 4u displayed a good inhibition of AChE (IC50value of 193?nM for eeAChE and 273?nM for hAChE), strong inhibition of BuChE (IC50value of 73?nM for eqBuChE and 56?nM for hBuChE), moderate inhibition of Aβ aggregation (56.3% at 20?μM) and good antioxidant activity (3.28?trolox equivalent by ORAC assay). Molecular modeling studies in combination with kinetic analysis revealed that 4u was a mixed-type inhibitor, binding simultaneously to catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE. In addition, 4u could chelate metal ions, reduce PC12 cells death induced by oxidative stress and penetrate the blood–brain barrier (BBB). Taken together, these results strongly indicated the hybridization approach is an efficient strategy to identify novel scaffolds with desired bioactivities, and further optimization of 4u may be helpful to develop more potent lead compound for AD treatment.

Structure - Activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: Evaluation of behavioral activity of O- and N-analogues and their binding to monoamine transporters

In our effort to develop a pharmacotherapy for the treatment of cocaine addiction, we embarked on synthesizing novel molecules targeting the dopamine transporter (DAT) molecule in the brain as DAT has been implicated strongly in the reinforcing effect of